Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?

The CERERRA database provides evidence that low-dose rituximab performs as well as the conventional dose in the real world, thus highlighting the possible pharmacoeconomic impact. In clinical trials, it has been shown that rituximab 500 mg twice, performs as well as 1 g twice, 2 weeks apart, in term...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferraccioli, Gianfranco, Tolusso, Barbara, Gremese, Elisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890326/
https://www.ncbi.nlm.nih.gov/pubmed/27255529
http://dx.doi.org/10.1186/s13075-016-1022-1
Descripción
Sumario:The CERERRA database provides evidence that low-dose rituximab performs as well as the conventional dose in the real world, thus highlighting the possible pharmacoeconomic impact. In clinical trials, it has been shown that rituximab 500 mg twice, performs as well as 1 g twice, 2 weeks apart, in terms of the American College of Rheumatology (ACR)20 and ACR50, but not the ACR70. The choice should always be made after considering that the IMAGE trial has demonstrated similar radiographic progression after the first 6 months, but with less control, with low-dose rituximab in the first 6 months. A possible alternative can be hypothesized.

Ejemplares similares